| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10019173 | HBV | ENSG00000120907.18 | protein_coding | ADRA1A | No | No | 148 | B0ZBD3 P35348 |
| TVIS10019323 | HBV | ENSG00000120907.18 | protein_coding | ADRA1A | No | No | 148 | B0ZBD3 P35348 |
| TVIS10031044 | HBV | ENSG00000120907.18 | protein_coding | ADRA1A | No | No | 148 | B0ZBD3 P35348 |
| TVIS10025139 | HBV | ENSG00000120907.18 | protein_coding | ADRA1A | No | No | 148 | B0ZBD3 P35348 |
| TVIS10020261 | HBV | ENSG00000120907.18 | protein_coding | ADRA1A | No | No | 148 | B0ZBD3 P35348 |
| TVIS10040464 | HBV | ENSG00000120907.18 | protein_coding | ADRA1A | No | No | 148 | B0ZBD3 P35348 |
| TVIS20001928 | HPV | ENSG00000120907.18 | protein_coding | ADRA1A | No | No | 148 | B0ZBD3 P35348 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ADRA1A |
|---|---|
| DrugBank ID | DB00706 |
| Drug Name | Tamsulosin |
| Target ID | BE0000501 |
| UniProt ID | P35348 |
| Regulation Type | antagonist |
| PubMed IDs | 11752352; 9352698; 10503165; 9352700; 8647141; 8647140; 19427736; 14680444 |
| Citations | Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Abrams P, Speakman M, Stott M, Arkell D, Pocock R: A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol. 1997 Oct;80(4):587-96.@@Na YJ, Guo YL, Gu FL: Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. J Med. 1998;29(5-6):289-304.@@Lee E, Lee C: Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol. 1997 Oct;80(4):606-11.@@Chapple CR, Wyndaele JJ, Nordling J, Boeminghaus F, Ypma AF, Abrams P: Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol. 1996;29(2):155-67.@@Schulman CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ: Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol. 1996;29(2):145-54.@@Chen Y, Li H, Dong Q, Wang KJ: Blockade of alpha 1A-adrenoceptor: a novel possible strategy for male contraception. Med Hypotheses. 2009 Aug;73(2):140-1. doi: 10.1016/j.mehy.2009.02.022. Epub 2009 May 8.@@Michel MC, de la Rosette JJ: Efficacy and safety of tamsulosin in the treatment of urological diseases. Expert Opin Pharmacother. 2004 Jan;5(1):151-60. |
| Groups | Approved; Investigational |
| Direct Classification | Amphetamines and derivatives |
| SMILES | CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O |
| Pathways | |
| PharmGKB | PA451583 |
| ChEMBL | CHEMBL836 |
